Health
Neurogastrx, Inc.
Neurogastrx is a Woburn, Massachusetts biopharmaceutical company developing therapies for gastrointestinal disorders rooted in the enteric nervous system. Its lead candidate, NG101, is an oral, peripherally acting dopamine D2 receptor antagonist (a proprietary mesylate salt of metopimazine) in late-stage development for gastroparesis and for the nausea and vomiting that limit GLP-1 weight-loss and diabetes drugs. Backed by roughly $105-125M from OrbiMed, 5AM Ventures and venBio, the company reported Phase 2 data in 2025 showing sizable reductions in GLP-1-induced nausea and vomiting.